Reuters logo
BRIEF-Celsion provides update on Thermodox in liver cancer study
September 27, 2017 / 1:04 PM / 2 months ago

BRIEF-Celsion provides update on Thermodox in liver cancer study

Sept 27 (Reuters) - Celsion Corp

* Celsion provides update on Thermodox® in the Phase III Optima study of primary liver cancer

* Celsion Corp -enrollment in Optima study is now approaching 70% of 550 patients necessary to ensure that its primary end point

* Celsion Corp-currently projects full patient enrollment by mid-2018 and 1st pre-planned efficacy analysis after 118 overall survival events by Q1 2019

* Celsion- co currently projects full patient enrollment by mid-2018 & 1st pre-planned efficacy analysis after 118 overall survival events by Q1 2019​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below